Clinical Trial Details
| Trial ID: | L5318 |
| Source ID: | NCT03490942 |
| Associated Drug: | Glucagon |
| Title: | Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses |
| Acronym: | |
| Status: | TERMINATED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT03490942/results |
| Conditions: | Hypoglycemia Unawareness|Diabetes Mellitus, Type 1 |
| Interventions: | DRUG: Glucagon|DRUG: Placebo |
| Outcome Measures: | Primary: Plasma Epinephrine, Plasma epinephrine concentration after 30 minutes of induced hypoglycemia. Change from baseline to the end of treatment will be assessed., 0-30 minutes | |
| Sponsor/Collaborators: | Sponsor: Xeris Pharmaceuticals | Collaborators: Integrated Medical Development |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE2 |
| Enrollment: | 49 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2018-03-15 |
| Completion Date: | 2020-02-10 |
| Results First Posted: | 2021-02-21 |
| Last Update Posted: | 2021-02-21 |
| Locations: | University of Alabama, Birmingham, Birmingham, Alabama, 35294, United States|University of California, San Diego, San Diego, California, 92037, United States|Emory University - Grady Memorial Hospital, Atlanta, Georgia, 30303, United States|Atlanta Diabetes Associates, Atlanta, Georgia, 30318, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States |
| URL: | https://clinicaltrials.gov/show/NCT03490942 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|